Karnataka Seeks Tougher Action Against Fake Drug Makers

The Karnataka government is considering stronger legal measures against people involved in manufacturing and selling counterfeit medicines, Health Minister U T Khader has said. He argued that cancelling licences or imposing financial penalties alone may not be enough when the alleged activity can put patients lives at risk.

Khader said the government wants the Centre to examine changes to the law so that people accused of deliberately putting human lives in danger through fake medicines can face severe criminal charges, including attempted murder or murder, depending on the circumstances established by investigators.

The minister made the remarks while discussing the investigation into a major counterfeit medicine case detected near Bidadi. Authorities had earlier seized suspected fake and expired medicines, along with related materials, valued at nearly Rs 5 crore. The case has since developed into an interstate investigation.

According to the preliminary investigation, medicines obtained from manufacturing centres in states including Telangana and Himachal Pradesh were allegedly brought into Karnataka, repackaged and relabelled before being distributed. Investigators are examining whether the network supplied medicines to medical shops, hospitals and clinics.

The suspected involvement of medicines used in critical care has made the case particularly serious. Authorities are trying to determine the route followed by the medicines and whether any of the seized products reached healthcare facilities before the enforcement operation.

A six member Special Investigation Team has been formed to investigate the case. The team includes police personnel along with officials from the Food Safety and Drug Administration and Commercial Taxes Department. The investigation is expected to examine the wider supply chain and identify people involved at different stages.

Investigators are also looking into documents connected with the alleged operation. Invoices, vouchers and other records could help establish where the medicines originated, who handled their transportation and which businesses may have received them.

The government has already directed hospitals and nursing homes in Karnataka not to use the seized medicines. Details of the suspected counterfeit products have also been communicated to the Union government and other states as authorities work to prevent their further circulation.

Khader has also sought assistance from the Centre. He said he had written to Union Health Minister J P Nadda requesting support from central drug regulatory authorities, including the Central Drugs Standard Control Organisation, to help trace the supply chain and examine the interstate links.

The possibility of a Central Bureau of Investigation probe is also being considered because of the scale and interstate nature of the case. Recent developments have included the arrest of a Bengaluru healthcare firm owner, while investigators continue to examine suspected supplies of counterfeit medicines and ICU injections to hospitals and clinics.

The minister has described the case as a warning about the risks created by counterfeit medicines entering the healthcare system. He said authorities would continue tracing the network and take action against those found responsible based on the evidence gathered during the investigation.

Alongside the investigation, Karnataka is examining ways to strengthen medicine quality checks. The government is considering establishing an advanced laboratory or working with an existing facility so that medicines collected randomly from manufacturers, hospitals and pharmacies can be tested more effectively.

Such testing could help authorities identify suspicious products earlier and provide another layer of protection for patients. The proposed measures would also give enforcement agencies better information when investigating complaints about medicines whose quality or authenticity is questioned.

The counterfeit medicine case has raised wider concerns about how easily products can move through complex pharmaceutical supply chains. When medicines are allegedly repackaged and sold under the names of established brands, identifying the original source can become difficult without detailed checks and documentation.

For patients and families, the issue is especially sensitive because medicines are often purchased at moments when there is little room for doubt about their quality. The government has therefore indicated that the investigation will focus not only on the people operating the suspected unit but also on the wider network involved in procurement, transportation and distribution.

The SIT investigation is now expected to establish the complete chain behind the suspected counterfeit medicines. Authorities will also examine records and other evidence to determine how widely the products were distributed and whether additional individuals or businesses were involved.

Khader has maintained that those found responsible should face strict action under the law. The government is also looking at stronger monitoring and testing mechanisms to reduce the possibility of counterfeit medicines entering the market in the future.

The case has consequently moved beyond a single seizure near Bidadi and into a broader investigation involving multiple agencies and possible interstate connections. The final findings of the investigation will determine the extent of the alleged network and the legal action that follows.

The Karnataka government is considering stronger legal measures against people involved in manufacturing and selling counterfeit medicines, Health Minister U T Khader has said. He argued that cancelling licences or imposing financial penalties alone may not be enough when the alleged activity can put patients lives at risk.

Khader said the government wants the Centre to examine changes to the law so that people accused of deliberately putting human lives in danger through fake medicines can face severe criminal charges, including attempted murder or murder, depending on the circumstances established by investigators.

The minister made the remarks while discussing the investigation into a major counterfeit medicine case detected near Bidadi. Authorities had earlier seized suspected fake and expired medicines, along with related materials, valued at nearly Rs 5 crore. The case has since developed into an interstate investigation.

According to the preliminary investigation, medicines obtained from manufacturing centres in states including Telangana and Himachal Pradesh were allegedly brought into Karnataka, repackaged and relabelled before being distributed. Investigators are examining whether the network supplied medicines to medical shops, hospitals and clinics.

The suspected involvement of medicines used in critical care has made the case particularly serious. Authorities are trying to determine the route followed by the medicines and whether any of the seized products reached healthcare facilities before the enforcement operation.

A six member Special Investigation Team has been formed to investigate the case. The team includes police personnel along with officials from the Food Safety and Drug Administration and Commercial Taxes Department. The investigation is expected to examine the wider supply chain and identify people involved at different stages.

Investigators are also looking into documents connected with the alleged operation. Invoices, vouchers and other records could help establish where the medicines originated, who handled their transportation and which businesses may have received them.

The government has already directed hospitals and nursing homes in Karnataka not to use the seized medicines. Details of the suspected counterfeit products have also been communicated to the Union government and other states as authorities work to prevent their further circulation.

Khader has also sought assistance from the Centre. He said he had written to Union Health Minister J P Nadda requesting support from central drug regulatory authorities, including the Central Drugs Standard Control Organisation, to help trace the supply chain and examine the interstate links.

The possibility of a Central Bureau of Investigation probe is also being considered because of the scale and interstate nature of the case. Recent developments have included the arrest of a Bengaluru healthcare firm owner, while investigators continue to examine suspected supplies of counterfeit medicines and ICU injections to hospitals and clinics.

The minister has described the case as a warning about the risks created by counterfeit medicines entering the healthcare system. He said authorities would continue tracing the network and take action against those found responsible based on the evidence gathered during the investigation.

Alongside the investigation, Karnataka is examining ways to strengthen medicine quality checks. The government is considering establishing an advanced laboratory or working with an existing facility so that medicines collected randomly from manufacturers, hospitals and pharmacies can be tested more effectively.

Such testing could help authorities identify suspicious products earlier and provide another layer of protection for patients. The proposed measures would also give enforcement agencies better information when investigating complaints about medicines whose quality or authenticity is questioned.

The counterfeit medicine case has raised wider concerns about how easily products can move through complex pharmaceutical supply chains. When medicines are allegedly repackaged and sold under the names of established brands, identifying the original source can become difficult without detailed checks and documentation.

For patients and families, the issue is especially sensitive because medicines are often purchased at moments when there is little room for doubt about their quality. The government has therefore indicated that the investigation will focus not only on the people operating the suspected unit but also on the wider network involved in procurement, transportation and distribution.

The SIT investigation is now expected to establish the complete chain behind the suspected counterfeit medicines. Authorities will also examine records and other evidence to determine how widely the products were distributed and whether additional individuals or businesses were involved.

Khader has maintained that those found responsible should face strict action under the law. The government is also looking at stronger monitoring and testing mechanisms to reduce the possibility of counterfeit medicines entering the market in the future.

The case has consequently moved beyond a single seizure near Bidadi and into a broader investigation involving multiple agencies and possible interstate connections. The final findings of the investigation will determine the extent of the alleged network and the legal action that follows.